Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects

DNA rich in nonmethylated CG motifs (CpGs) greatly facilitates induction of immune responses against coadministered Ags. CpGs are therefore among the most promising adjuvants known to date. Nevertheless, CpGs are characterized by two drawbacks. They have unfavorable pharmacokinetics and may exhibit systemic side effects, including splenomegaly. We show in this study that packaging CpGs into virus-like particles (VLPs) derived from the hepatitis B core Ag or the bacteriophage Qβ is a simple and attractive method to reduce these two problems. CpGs packaged into VLPs are resistant to DNase I digestion, enhancing their stability. In addition, and in contrast to free CpGs, packaging CpGs prevents splenomegaly in mice, without affecting their immunostimulatory capacity. In fact, vaccination with CpG-loaded VLPs was able to induce high frequencies of peptide-specific CD8+ T cells (4–14%), protected from infection with recombinant vaccinia viruses, and eradicated established solid fibrosarcoma tumors. Thus, packaging CpGs into VLPs improves both their immunogenicity and pharmacodynamics.

[1]  M. Bally,et al.  Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. , 2003, Vaccine.

[2]  P. Wingfield,et al.  Characterization of a Conformational Epitope on Hepatitis B Virus Core Antigen and Quasiequivalent Variations in Antibody Binding , 2003, Journal of Virology.

[3]  A. Jegerlehner,et al.  A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. , 2002, Vaccine.

[4]  J. Reimann,et al.  Priming Th1 Immunity to Viral Core Particles Is Facilitated by Trace Amounts of RNA Bound to Its Arginine-Rich Domain1 , 2002, The Journal of Immunology.

[5]  A. Jegerlehner,et al.  Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles1 , 2002, The Journal of Immunology.

[6]  F. Lechner,et al.  Cross‐presentation of virus‐like particles by skin‐derived CD8– dendritic cells: a dispensable role for TAP , 2002, European journal of immunology.

[7]  F. Marincola,et al.  Intensity of the Vaccine-Elicited Immune Response Determines Tumor Clearance , 2002, The Journal of Immunology.

[8]  Y. Kawarada,et al.  NK- and CD8+ T Cell-Mediated Eradication of Established Tumors by Peritumoral Injection of CpG-Containing Oligodeoxynucleotides1 , 2001, The Journal of Immunology.

[9]  K. Ishii,et al.  Cutting Edge: Role of Toll-Like Receptor 9 in CpG DNA-Induced Activation of Human Cells1 , 2001, The Journal of Immunology.

[10]  K. Ishii,et al.  Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides1 , 2001, The Journal of Immunology.

[11]  S. Akira,et al.  Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.

[12]  H. Wagner,et al.  Toll meets bacterial CpG-DNA. , 2001, Immunity.

[13]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[14]  P. Pumpens,et al.  Mutilation of RNA phage Qβ virus‐like particles: from icosahedrons to rods , 2000, FEBS letters.

[15]  S. Akira,et al.  The role of Toll-like receptors and MyD88 in innate immune responses , 2000, Journal of endotoxin research.

[16]  R. Zinkernagel,et al.  In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. , 2000, Vaccine.

[17]  A. Krieg,et al.  The role of CpG motifs in innate immunity. , 2000, Current opinion in immunology.

[18]  G. Hartmann,et al.  CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Leslie,et al.  The crystal structure of the human hepatitis B virus capsid. , 1999, Molecular cell.

[20]  L. Hültner,et al.  Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. , 1999, Journal of immunology.

[21]  K. Heeg,et al.  Bacterial DNA as immune cell activator. , 1998, Trends in microbiology.

[22]  R. Zinkernagel,et al.  Cutting Edge Commentary: Immune Responses in the Absence of Costimulation: Viruses Know the Trick , 1998, The Journal of Immunology.

[23]  J. Sprent,et al.  DNA as an Adjuvant: Capacity of Insect DNA and Synthetic Oligodeoxynucleotides to Augment T Cell Responses to Specific Antigen , 1998, The Journal of experimental medicine.

[24]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[25]  L. Manzel,et al.  Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. , 1998, Journal of immunology.

[26]  A. Krieg,et al.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. , 1998, Journal of immunology.

[27]  C. Harding,et al.  CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity , 1997, The Journal of experimental medicine.

[28]  C. Blank,et al.  CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants , 1997, European journal of immunology.

[29]  D. Richman,et al.  Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants , 1997, Nature Medicine.

[30]  K. Heeg,et al.  Bacterial DNA causes septic shock , 1997, Nature.

[31]  C. Janeway,et al.  Innate immunity: impact on the adaptive immune response. , 1997, Current opinion in immunology.

[32]  A. Krieg,et al.  IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. , 1996, Journal of immunology.

[33]  Rolf M. Zinkernagel,et al.  Immunology Taught by Viruses , 1996, Science.

[34]  F. Hobbs,et al.  Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides. , 1995, Molecular pharmacology.

[35]  R. Ueda,et al.  Immune function in mice lacking the perforin gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Zinkernagel,et al.  Induction of protective cytotoxic T cells with viral proteins , 1994, European journal of immunology.

[37]  R. A. Crowther,et al.  Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy , 1994, Cell.

[38]  Hans Hengartner,et al.  Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice , 1994, Nature.

[39]  G. Trainor,et al.  Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. , 1994, Molecular pharmacology.

[40]  Y. Cheng,et al.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical? , 1993, Science.

[41]  R M Zinkernagel,et al.  Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. , 1991, Journal of virological methods.

[42]  R. Medzhitov CpG DNA: security code for host defense , 2001, Nature Immunology.

[43]  H. Häcker,et al.  Signal transduction pathways activated by CpG-DNA. , 2000, Current topics in microbiology and immunology.

[44]  P. Pumpens,et al.  RNA Phage Qβ Coat Protein as a Carrier for Foreign Epitopes , 1996 .

[45]  M. Battegay [Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24 well plates] , 1993, ALTEX.

[46]  C. Janeway Approaching the asymptote? Evolution and revolution in immunology. , 1989, Cold Spring Harbor symposia on quantitative biology.